Related Experiment Video
Updated: Jun 10, 2025
Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle
Published on: February 1, 2017
Development of a Monocyte Activation Test for Evaluating Recombinant Hepatitis B Vaccine: A Novel Approach for
Delaram Doroud1, Zohre Eftekhari2, Mojtaba Daneshi3
1Pasteur Institute of Iran, Tehran, Iran.
Background:
Injectable products, particularly human vaccines, must be free from fever-inducing agents and thoroughly tested for pyrogens as part of a quality control. Consequently, manufacturing facilities are required to conduct ppropriate pyrogen tests per pharmacopoeial standards. This study aimed to evaluate the reliability of the monocyte activation test (MAT) in quantifying pyrogenic content in the recombinant hepatitis B vaccine.
Methods:
We assessed pyrogen activity in the active pharmaceutical ingredient (API), formulated vaccine, and aluminum hydroxide by comparing the limulus amebocyte lysate (LAL), rabbit pyrogen test (RPT), and MAT, measuring activity in relative pyrogen unit (RPU) as per the European Pharmacopoeia. Monocytes from healthy donors were isolated and identified via flow cytometry to measure the CD14+ marker frequency.
Results:
The study found that the pyrogenic concentration of lipoteichoic acid (LTA) in the MAT was 50,000 ng/mL (5.19 EEU/mL). In contrast, the same concentration in the rabbit pyrogen test (RPT) was deemed non-pyrogenic based on rectal temperature assessments. The MAT showed sensitivity to the API and adjuvant, with a detection limit of 2.5 EU/mL for IL-6, outperforming the RPT, which had a detection limit of 5 EU/mL.
Conclusion:
A strong IL-6 response to both lipopolysaccharide (LPS) and LTA stimulation was observed, indicating that IL-6 could serve as a valuable marker for pyrogen testing. The MAT appears to be an effective alternative to the RPT for assessing pyrogenicity, demonstrating commendable consistency and accuracy across various testing systems allowed by the Ph. Eur. General MAT Chapter, especially given the RPT's limitations in controlling pyrogenicity in injectable products.
